Description
A dual inhibitor of EGFR and ErbB2 (IC50s = 19 and 3 nM, respectively); inhibits the growth of EGFR-overexpressing A431 skin cancer and ErbB2-overexpressing SK-BR-3 breast cancer cells (IC50s = 0.14 and 0.124 μM, respectively); inhibits the growth of ErbB2-amplified OD19 esophageal and NCI-N87 gastric cancer cells (IC50s = 0.09 and 0.01 μM, respectively); inhibits the growth of gastric cancer cells in which ErbB2 is not amplified (IC50s = 0.35-8.58 μM); induces apoptosis in NCI-N87 and OD19 cells at 1 μM; reduces tumor growth in a BT474 breast cancer mouse xenograft model at 50 mg/kg; reduces tumor growth in an NCI-N87 mouse xenograft model at 100 mg/kg and induces tumor regression when used in combination with trastuzumab
Formal name: N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine
Synonyms: GSK 572016|GW 572016
Molecular weight: 581.1
CAS: 231277-92-2
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|EGFR/ErbB/HER Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling